These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31644379)

  • 1. Home induction and outpatient treatment of kratom use disorder with buprenorphine-naloxone: A case report in a young adult.
    Schmuhl KK; Gardner SM; Cottrill CB; Bonny AE
    Subst Abus; 2020; 41(3):311-314. PubMed ID: 31644379
    [No Abstract]   [Full Text] [Related]  

  • 2. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term buprenorphine treatment for kratom use disorder: A case series.
    Broyan VR; Brar JK; Allgaier Student T; Allgaier JT
    Subst Abus; 2022; 43(1):763-766. PubMed ID: 35112990
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Kratom Dependence With Buprenorphine-Naloxone Maintenance.
    Buresh M
    J Addict Med; 2018; 12(6):481-483. PubMed ID: 29944481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Potential Pharmacokinetic Kratom-drug Interactions Resulting in Toxicity and Subsequent Treatment of Kratom Use Disorder With Buprenorphine/Naloxone.
    Brogdon HD; McPhee MM; Paine MF; Cox EJ; Burns AG
    J Addict Med; 2022 Sep-Oct 01; 16(5):606-609. PubMed ID: 35165231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program.
    Smith KE; Lawson T
    Drug Alcohol Depend; 2017 Nov; 180():340-348. PubMed ID: 28950240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy.
    Smid MC; Charles JE; Gordon AJ; Wright TE
    Obstet Gynecol; 2018 Oct; 132(4):926-928. PubMed ID: 30204686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment.
    Grist E; Thakkar B; Dacha P; Lutins E; Maxwell M; Martin CE
    J Addict Med; 2023 Mar-Apr 01; 17(2):215-218. PubMed ID: 36730907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-naloxone therapy in pain management.
    Chen KY; Chen L; Mao J
    Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
    Randall A; Hull I; Martin SA
    J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for kratom abuse in a contingency-management-based MAT setting: A case series.
    Kalin S; Dakhlalla S; Bhardwaj S
    J Opioid Manag; 2020 Sep/Oct 2020; 16(5):391-394. PubMed ID: 33226096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kratom and opioid use disorder in the perioperative period: A case report on the expanding role of buprenorphine.
    Perez J
    J Opioid Manag; 2023; 19(1):91-93. PubMed ID: 36683304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Need for clarity and context in case reports on kratom use, assessment, and intervention.
    Smith KE; Dunn KE; Epstein DH; Feldman JD; Garcia-Romeu A; Grundmann O; Henningfield JE; McCurdy CR; Rogers JM; Schriefer D; Singh D; Weiss ST
    Subst Abus; 2022; 43(1):1221-1224. PubMed ID: 35657649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.